Newsroom
Sorted by: Latest
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF 10% - January 14.05.2026 FJAN.LN IE000MDKBOB3 150,002.00 USD 4,290,059.63 28.600 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Nasdaq Clean Edge Global Water UCITS ETF 14.05.2026 H2O LN IE000Q8F0M81 600,002.00 USD 11,925,015.76 19.875 ...
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Cizzle Brands Corporation Announces the Launch of CWENCH Hydration™ at Save-On-Foods Across Western Canada
TORONTO--(BUSINESS WIRE)--Cizzle Brands Corporation (Cboe Canada: CZZL; OTCQB: CZZLF; Frankfurt: 8YF) (“Cizzle Brands” or the “Company”), the vertically integrated sports nutrition company that is elevating the game in health and wellness, today announced that CWENCH Hydration™ is now available at more than 170 Save-On-Foods locations across Western Canada. At launch, Save-On-Foods will be carrying an assortment of three of CWENCH Hydration’s most popular ready-to-drink (“RTD”) flavours – Blue...
-
SBC Medical Group Holdings annonce ses résultats financiers pour le premier trimestre 2026
IRVINE, Californie--(BUSINESS WIRE)--SBC Medical Group Holdings Incorporated (Nasdaq : SBC) (« SBC Medical » ou la « société »), une organisation de services médicaux fournissant un soutien en matière de gestion dans un large éventail de domaines de la santé, a annoncé aujourd’hui ses résultats financiers pour le trimestre clos le 31 mars 2026. Chiffres du premier trimestre 2026 Le chiffre d’affaires total s’est élevé à 43 millions de dollars, soit une baisse de 9 % d’une année sur l’autre. Le...
-
Vecima to Highlight Next-Generation 50G-PON, DOCSIS® 4.0 vCMTS, AI & Automation, and Monetizable Streaming at ANGA COM 2026
VICTORIA, British Columbia--(BUSINESS WIRE)--Vecima will highlight its leadership at ANGA COM 2026, showcasing AI-powered network operations, cloud-native DOCSIS 4.0 access, and fiber solutions....
-
Meiji Seika Pharma : résultats positifs de l’essai de phase III Integral-1 sur le nacubactam, un nouvel inhibiteur de β-lactamase, dans le traitement des infections compliquées des voies urinaires ou de la pyélonéphrite aiguë non compliquée...
TOKYO--(BUSINESS WIRE)-- Meiji Seika Pharma : résultats positifs de l’essai de phase III Integral-1 sur le nacubactam, un nouvel inhibiteur de β-lactamase, dans le traitement des infections compliquées des voies urinaires ou de la pyélonéphrite aiguë non compliquée ― Publiés dans The Lancet Meiji Seika Pharma Co., Ltd. (siège social à Tokyo ; président-directeur général : Toshiaki Nagasato) a annoncé aujourd’hui que les résultats de l’étude Integral-1, l’un des deux essais cliniques mondiaux d...
-
REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 2026
TURIN, Italy--(BUSINESS WIRE)--Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2026. Since the beginning of the year, the Group has recorded a consolidated revenues amounting to €645.0 million, an increase of 6.2% compared to the corresponding data for 2025. All indicators are positive for the period. In the first quarter of 2026 the consolidated EBITDA stood at €112.0 million compared to €105.3 million in 2025, equal to 17.4% of the turnover....